YOLFTbeta
Chengdu Easton Biopharmaceuticals Co Ltd

Chengdu Easton Biopharmaceuticals Co Ltd

688513 · SHG · Healthcare / Biotechnology

40.89CNY-1.81 (-4.24%)

Price History

Full chart

Market Stats

Previous Close42.70
Open42.57
Day Range40.78 – 42.73
52-Week Range40.25 – 79.67
Volume2.21M
Market Cap9.03B
P/E (TTM)31.98
Forward P/E0.00
EPS1.60
Dividend Yield0.96%
Beta0.04
50-Day Avg47.20
200-Day Avg55.99

About

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. Its products are used in oncology, cardiovascular, neurology and psychiatry, anesthetic and analgesics, urinary, anti-inflammatory, anti-diabetes, anthelmintic, and antiemetic therapeutic categories. The company was founded in 2009 and is headquartered in Chengdu, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Mingxu Yuan
  • Employees1.42K
  • HeadquartersNo. 8, Ankang Road, Chengdu, China, 610200, China
  • Websitehttps://www.eastonpharma.cn

Leadership

  • Mr. Mingxu YuanGM & Director · b. 1972
  • Ms. Xiao Qin BoCFO & Director · b. 1982
  • Mr. Daming ZhangDeputy GM & Director · b. 1973
  • Ms. Shuyun LiBoard Secretary · b. 1985
  • Mr. Zheng Pin GuanDeputy GM & Core Technician · b. 1974
  • Mr. Xingyao SongDeputy General Manager · b. 1977

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue162.50M208.74M240.72M338.80M476.34M768.76M947.24M921.92M1.02B1.17B1.12B1.35B1.33B
Growth (%)-+28.46%+15.32%+40.75%+40.59%+61.39%+23.22%-2.67%+10.96%+14.43%-4.56%+20.82%-1.36%
Cost of Revenue93.63M104.89M107.97M70.28M73.07M89.19M95.82M107.68M146.32M199.11M226.94M345.23M329.52M
Gross Profit68.87M103.85M132.75M268.53M403.27M679.57M851.42M814.23M876.62M971.40M890.18M1.00B1.33B
Gross Margin42.38%49.75%55.15%79.26%84.66%88.40%89.88%88.32%85.70%82.99%79.68%74.42%100.00%
Operating Expense56.06M75.65M91.13M229.11M329.00M530.43M736.69M615.44M632.46M710.77M648.44M752.55M1.02B
Operating Income12.81M28.20M41.62M39.42M74.27M149.14M114.73M198.80M244.15M260.63M241.74M251.98M312.52M
Operating Margin7.88%13.51%17.29%11.63%15.59%19.40%12.11%21.56%23.87%22.27%21.64%18.67%23.47%
EBITDA24.28M46.87M63.72M61.62M97.86M173.20M143.58M232.94M280.10M322.94M318.55M337.88M380.75M
EBITDA Margin14.94%22.46%26.47%18.19%20.54%22.53%15.16%25.27%27.38%27.59%28.52%25.03%28.60%
Net Income14.73M29.23M37.62M57.32M64.37M135.02M108.61M178.16M232.43M246.52M226.57M238.23M283.25M
Net Income Margin9.07%14.00%15.63%16.92%13.51%17.56%11.47%19.33%22.72%21.06%20.28%17.65%21.27%
R&D24.93M27.97M33.50M45.56M77.22M124.40M156.57M153.91M200.70M230.79M238.49M263.86M265.06M
R&D as % of Total Revenue15.34%13.40%13.91%13.45%16.21%16.18%16.53%16.69%19.62%19.72%21.35%19.55%19.91%
Interest Expense---9.24K92.13K132.61K171.93K911.70K577.33K2.61M3.68M3.92M2.51M
Interest Expense % of Total Revenue---0.00%0.02%0.02%0.02%0.10%0.06%0.22%0.33%0.29%0.19%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets254.86M283.10M311.63M520.22M591.98M789.69M987.08M2.53B2.78B3.02B3.35B3.40B3.80B
Total Liabilities86.24M79.85M43.42M130.43M146.70M207.50M289.64M435.61M483.60M573.08M743.33M702.21M-2.87B
Total Equity157.44M187.34M244.33M389.79M445.28M582.19M697.44M2.10B2.29B2.44B2.60B2.70B2.87B
Cash28.84M50.25M71.60M227.04M272.77M364.78M404.06M1.06B1.05B830.97M781.23M971.40M855.43M
Total Debt40.00M24.18M3.57M---4.69M40.03M20.02M105.29M220.55M110.37M-
Net Debt11.16M-26.07M-68.03M-227.04M-272.77M-364.78M-399.36M-1.02B-1.03B-725.67M-560.68M-861.03M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow28.12M46.71M50.57M106.06M85.70M166.79M141.83M156.52M147.60M151.94M275.25M263.24M264.94M
Investing Cash Flow-59.58M-8.38M-33.64M-20.39M-14.11M-74.81M-87.99M-756.63M-110.59M-405.70M-410.17M196.63M-
Financing Cash Flow14.64M-13.38M847.48K69.72M-26.50M--13.86M1.25B-56.40M39.70M80.67M-262.27M-
Capital Expenditure76.11M22.04M35.43M17.83M23.02M76.63M95.41M198.81M256.29M339.33M175.26M117.42M86.28M
Free Cash Flow-47.99M24.67M15.13M88.23M62.68M90.15M46.42M-42.28M-108.69M-187.38M99.99M145.82M178.66M
Dividends Paid2.38M2.53M--22.50M-22.50M696.28K36.03M93.67M71.08M74.11M76.79M
FCF to OCF-170.68%52.82%29.93%83.19%73.14%54.05%32.73%-27.01%-73.64%-123.32%36.33%55.39%67.43%
Dividend Paid to FCF-4.95%10.25%--35.90%-48.47%-1.65%-33.15%-49.99%71.08%50.82%42.98%

Earnings

Report DateSep 30, 2020Mar 30, 2021Apr 16, 2021Jul 29, 2021Oct 21, 2021Feb 25, 2022Apr 22, 2022Jul 27, 2022Oct 20, 2022Dec 31, 2022Apr 27, 2023Aug 17, 2023
EPS Estimate------------
EPS Actual0.320.440.360.620.570.390.450.670.510.420.430.59
Surprise------------
Timing-After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketAfter-hours

Key Statistics & Ratios

Market Cap9.03B
Enterprise Value7.66B
Trailing P/E31.98
Forward P/E0.00
Price / Sales6.76
Price / Book3.13
EPS1.60
Book Value16.90
Revenue (TTM)1.34B
Gross Profit (TTM)1.00B
EBITDA262.93M
Profit Margin20.75%
Operating Margin16.15%
Return on Equity8.59%
Return on Assets2.71%
Shares Outstanding176.53M
Shares Float81.29M
Beta0.04
Dividend Yield0.96%
Dividend Rate0.49
Payout Ratio30.63%

Dividends

20261×
0.49Jun 2, 2026
20251×
0.43Jun 11, 2025
20241×
0.58Jul 1, 2024
20231×
0.38May 23, 2023
20221×
0.53Apr 29, 2022
20211×
0.20May 17, 2021

Stock Splits

  • Jul 1, 20241.47:1